FDA Approves Five-Day Dosing Regimen For Dacogen(R) (decitabine) For Injection, Offering A New Outpatient Dosing …
Eisai Inc announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen …
Read more on Medical News Today
